D Vitamini Zehirlenmesi

Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev. 2016;96(1):365-408. doi: 10.1152/physrev.00014.2015.

Holick MF. The D-lightful vitamin D for child health. J Parenter Enteral Nutr. 2012;36(1 suppl):9S–19S.

Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319-329. doi: 10.1016/j.chembiol.2013.12.016.

Misra M, Pacaud D, Petryk A, et al. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122(2):398-417. doi: 10.1542/peds.2007-1894.

Silva ICJ, Lazaretti-Castro M. Vitamin D metabolism and extraskeletal outcomes: an update. Arch Endocrinol Metab. 2022;66(5):748-755. doi: 10.20945/2359-3997000000565.

Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, et al. Vitamin D Toxicity-A Clinical Perspective. Front Endocrinol (Lausanne). 2018;9:550. doi: 10.3389/fendo.2018.00550.

Stokes VJ, Nielsen MF, Hannan FM, et al. Hypercalcemic Disorders in Children. J Bone Miner Res. 2017;32(11):2157-2170. doi: 10.1002/jbmr.3296.

Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocr Rev. 2016;37(5):521-547. doi: 10.1210/er.2016-1070.

Baştuğ F, Gündüz Z, Tülpar S, et al. Urolithiasis in infants: evaluation of risk factors. World J Urol. 2013;31(5):1117-1122. doi: 10.1007/s00345-012-0828-y.

Galior K, Grebe S, Singh R. Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case Reports. Nutrients. 2018;10(8):953. doi: 10.3390/nu10080953.

Holmlund-Suila E, Viljakainen H, Hytinantti T, et al. High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and bone strength. J Clin Endocrinol Metab. 2012;97(11):4139-4147. doi: 10.1210/jc.2012-1575.

Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365(5):410-421. doi: 10.1056/NEJMoa1103864.

Vogiatzi MG, Jacobson-Dickman E, DeBoer MD. Drugs, and Therapeutics Committee of The Pediatric Endocrine Society. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. J Clin Endocrinol Metab. 2014;99(4):1132-1141. doi: 10.1210/jc.2013-3655.

Bikle DD. Vitamin D: Production, Metabolism and Mechanisms of Action. In: Endotext. MDText.com, Inc., South Dartmouth (MA); 2000. PMID: 25905172.

Gupta AK, Jamwal V, Sakul MP, et al. Hypervitaminosis D and systemic manifestations: a comprehensive review. JIMSA. 2014;27(4):236-237.

Granado-Lorencio F, Rubio E, Blanco-Navarro I, et al. Hypercalcemia, hypervitaminosis A and 3-epi-25-OH-D3 levels after consumption of an “over the counter” vitamin D remedy. A case report. Food Chem Toxicol. 2012;50:2106–2108.

Lin TH, Lu HJ, Lin CH, et al. Nephrocalcinosis in children who received high-dose vitamin D. Pediatr Nephrol. 2022;37(10):2471-2478. doi: 10.1007/s00467-022-05512-6.

Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947. doi:10.1210/clinem/dgae290.

Sagsak E, Savas-Erdeve S, Keskin M, et al. The use of pamidronate for acute vitamin D intoxication, clinical experience with three cases. J Pediatr Endocrinol Metab. 2015;28(5-6):709-712. doi: 10.1515/jpem-2014-0279. PMID: 25581744.

Ozkan B, Hatun S, Bereket A. Vitamin D intoxication. Turk J Pediatr. 2012;54(2):93-98.

Simm PJ, Biggin A, Zacharin MR, et al. APEG Bone Mineral Working Group. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54(3):223-233. doi: 10.1111/jpc.13768.

Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18(2):153-165. doi: 10.1007/s11154-017-9424-1.

Wright JD, Tergas AI, Ananth CV, et al. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy. Cancer Invest. 2015;33(8):331-339. doi: 10.3109/07357907.2015.1047506.

Bhavani N, Praveen VP, Jayakumar RV, et al. Hypercalcemia with renal failure. J Assoc Physicians India. 2012;60:52-54.

Khan AA, Gurnani PK, Peksa GD, et al. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy. Ann Pharmacother. 2021;55(3):277-285. doi: 10.1177/1060028020957048.

Zhao H, Ding Y, Yang J, et al. Efficacy and safety of bisphosphonates on childhood osteoporosis secondary to chronic illness or its treatment: a meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223221129163. doi: 10.1177/20406223221129163.

Bowden SA, Mahan JD. Zoledronic acid in pediatric metabolic bone disorders. Transl Pediatr. 2017;6(4):256-268. doi: 10.21037/tp.2017.09.10.

Comparison of Treatment Regimens in Management of Severe Hypercalcemia Due to Vitamin D Intoxication in Children. J Clin Res Pediatr Endocrinol. 2019;11(2):140-148. doi:10.4274/jcrpe.galenos.2018.2018.0131

Zieg J, Ghose S, Raina R. Electrolyte disorders related emergencies in children. BMC Nephrol. 2024;25(1):282. doi: 10.1186/s12882-024-03725-5.